Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 18180371)


Evaluation of melting curve analysis for screening the most prevalent mutations in topoisomerase genes from Streptococcus pneumoniae.

Melano RG, Higgins R, Seah C, Drews SJ.

J Clin Microbiol. 2008 Jan;46(1):396-7; author reply 397. doi: 10.1128/JCM.01924-07. No abstract available.


Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.

Page S, Vernel-Pauillac F, O'Connor O, Bremont S, Charavay F, Courvalin P, Goarant C, Le Hello S.

Antimicrob Agents Chemother. 2008 Nov;52(11):4155-8. doi: 10.1128/AAC.00082-08. Epub 2008 Aug 25.


In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.

Touyama M, Higa F, Nakasone C, Shinzato T, Akamine M, Haranaga S, Tateyama M, Nakasone I, Yamane N, Fujita J.

J Antimicrob Chemother. 2006 Dec;58(6):1279-82. Epub 2006 Oct 20.


An extended PCR-RFLP assay for detection of parC, parE and gyrA mutations in fluoroquinolone-resistant Streptococcus pneumoniae.

Alonso R, Galimand M, Courvalin P.

J Antimicrob Chemother. 2004 Apr;53(4):682-3. Epub 2004 Mar 10. No abstract available.


DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.

Park HS, Jung SJ, Kwak JH, Choi DR, Choi EC.

Int J Antimicrob Agents. 2010 Jul;36(1):97-8. doi: 10.1016/j.ijantimicag.2010.02.022. Epub 2010 Apr 18. No abstract available.


[MALDI-ToF mass-spectrometry in analysis of genetically determined resistance of Streptococcus pneumoniae to fluoroquinolones].

Malakhova MV, Vereshchagin VA, Il'ina EN, Govorun VM, Filimonova OIu, Grudinina SA, Sidorenko SV.

Antibiot Khimioter. 2007;52(1-2):10-7. Russian.


Molecular characterization of genes encoding the quinolone resistance determining regions of Malaysian Streptococcus pneumoniae strains.

Kumari N, Subramaniam G, Navaratnam P, Sekaran SD.

Indian J Med Microbiol. 2008 Apr-Jun;26(2):148-50.


Novel symmetric and asymmetric DNA scission determinants for Streptococcus pneumoniae topoisomerase IV and gyrase are clustered at the DNA breakage site.

Leo E, Gould KA, Pan XS, Capranico G, Sanderson MR, Palumbo M, Fisher LM.

J Biol Chem. 2005 Apr 8;280(14):14252-63. Epub 2005 Jan 18.


In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations.

De Vecchi E, Nicola L, Ossola F, Drago L.

J Antimicrob Chemother. 2009 Apr;63(4):721-7. doi: 10.1093/jac/dkp020. Epub 2009 Feb 13.


[Streptococcus agalactiae highly resistant to fluoroquinolones].

Miró E, Rebollo M, Rivera A, Alvarez MT, Navarro F, Mirelis B, Coll P.

Enferm Infecc Microbiol Clin. 2006 Nov;24(9):562-3. Spanish.


Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims.

Smith HJ, Nichol KA, Hoban DJ, Zhanel GG.

J Antimicrob Chemother. 2002 Jun;49(6):893-5. Review. No abstract available.


Molecular characterization of high-level fluoroquinolone resistance in a clinical isolate of Haemophilus parainfluenzae.

Rodríguez-Martínez JM, López-Hernández I, Pascual A.

J Antimicrob Chemother. 2011 Mar;66(3):673-5. doi: 10.1093/jac/dkq473. Epub 2010 Dec 1. No abstract available.


[Gene sequencing analysis of DNA gyrase and topoisomerase IV as levofloxacin resistance in Streptococcus pneumoniae].

Miyamoto H, Murase M.

Kansenshogaku Zasshi. 2002 Oct;76(10):898-9. Japanese. No abstract available.


Fluoroquinolone resistance in a clinical isolate of Streptococcus pneumoniae in the South Pacific.

Le Hello S, Page S, Garin B.

Int J Antimicrob Agents. 2008 Jul;32(1):91-2. doi: 10.1016/j.ijantimicag.2008.02.015. Epub 2008 May 20. No abstract available.


Melting curve analysis for rapid detection of topoisomerase gene mutations in Haemophilus influenzae.

Nakamura S, Yanagihara K, Morinaga Y, Izumikawa K, Seki M, Kakeya H, Yamamoto Y, Kamihira S, Kohno S.

J Clin Microbiol. 2009 Mar;47(3):781-4. doi: 10.1128/JCM.01645-08. Epub 2009 Jan 7.


Rapid screening of topoisomerase gene mutations by a novel melting curve analysis method for early warning of fluoroquinolone-resistant Streptococcus pneumoniae emergence.

Fukushima KY, Hirakata Y, Sugahara K, Yanagihara K, Kondo A, Kohno S, Kamihira S.

J Clin Microbiol. 2006 Dec;44(12):4553-8. Epub 2006 Oct 4.


Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a preexisting parC mutation.

de Cueto M, Rodríguez JM, Soriano MJ, López-Cerero L, Venero J, Pascual A.

J Clin Microbiol. 2008 Apr;46(4):1558-60. doi: 10.1128/JCM.02066-07. Epub 2008 Feb 20.


New real-time PCR assay using locked nucleic acid probes to assess prevalence of ParC mutations in fluoroquinolone-susceptible Streptococcus pneumoniae isolates from France.

Decousser JW, Methlouthi I, Pina P, Collignon A, Allouch P; ColBVH Study Group.

Antimicrob Agents Chemother. 2006 Apr;50(4):1594-8.


Clerocidin interacts with the cleavage complex of Streptococcus pneumoniae topoisomerase IV to induce selective irreversible DNA damage.

Richter SN, Leo E, Giaretta G, Gatto B, Fisher LM, Palumbo M.

Nucleic Acids Res. 2006 Apr 13;34(7):1982-91. Print 2006.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk